Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464969 · ClinicalTrials.gov registry record · Phase 4
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 229
- Enrollment target
NCT02464969 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 229 participants.
The verdict
NCT02464969, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 229 participants
- Enrollment target
Study Summary
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Interventions
- DRUG Apixaban
- DRUG Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2015-11-22 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464969
The ClinicalTrials.gov registry entry for NCT02464969 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02464969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02464969 about?
NCT02464969 is a clinical study titled "Apixaban for the Acute Treatment of Venous Thromboembolism in Children". To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
What is the current status of trial NCT02464969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 229 participants. The study started on 2015-11-22. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT02464969?
The interventions under investigation include: Apixaban (DRUG), Standard of Care (DRUG).
Who is sponsoring clinical trial NCT02464969?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.